Merck Builds New Production Plant for Pharmaceutical Raw Materials
- New plant for the production of inorganic salts by crystallization
- Investment of around € 30 million
- Laboratory Business and Life Science Solutions are strengthened
“The cornerstone has been laid for a key investment in the future,” said Klaus R. Bischoff, Head of the Performance & Life
Science Chemicals division at Merck. “As a supplier of key technologies, we want to grow along with our customers in the pharmaceutical
and biopharmaceutical industries. This expansion of capacity and modernization is our response to the growing global demand
for and high requirements placed on quality and product safety for final pharmaceutical and biopharmaceutical formulations.
At the same time, the new plant is a strong commitment to Darmstadt as a Merck chemical production site.”
The modernization measures in inorganic chemical production are part of the growth strategy for Merck’s units Life Science Solutions and Laboratory Business, both within the division Performance & Life Science Chemicals. After the construction of the new materials research center, which will be opened in Darmstadt this year, this is one of Merck’s largest chemical investments worldwide.
In Life Science Solutions, Merck has an extensive product range and supports its customers in all phases of the drug manufacturing process, from research, industrial production and quality control, through to service in concrete safety and regulatory issues.
Merck’s Laboratory Business is one of the leading suppliers of laboratory chemicals to research, teaching and industrial establishments, offering an extensive range of products, for example suitable for analytical chromatography, microbiology, food and environmental analysis, and pharmaceutical research. Reagents for analytical and general applications as well as solvents, salts, acids, alkalis and organic chemicals round off the portfolio.
The modernization measures in inorganic chemical production are part of the growth strategy for Merck’s units Life Science Solutions and Laboratory Business, both within the division Performance & Life Science Chemicals. After the construction of the new materials research center, which will be opened in Darmstadt this year, this is one of Merck’s largest chemical investments worldwide.
In Life Science Solutions, Merck has an extensive product range and supports its customers in all phases of the drug manufacturing process, from research, industrial production and quality control, through to service in concrete safety and regulatory issues.
Merck’s Laboratory Business is one of the leading suppliers of laboratory chemicals to research, teaching and industrial establishments, offering an extensive range of products, for example suitable for analytical chromatography, microbiology, food and environmental analysis, and pharmaceutical research. Reagents for analytical and general applications as well as solvents, salts, acids, alkalis and organic chemicals round off the portfolio.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go
to http://www.merck.de/subscribe to register online, change your selection or discontinue this service.
Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore) employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
